InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| HEK-Blue™ Selection | Modulation of outer membrane vesicle-based immune responses by cathelicidins. | 2022 | Vaccine | Balhuizen M.D. et al. | DOI: 10.1016/j.vaccine.2022.03.015 |
| Blasticidin | Modulation of outer membrane vesicle-based immune responses by cathelicidins. | 2022 | Vaccine | Balhuizen M.D. et al. | DOI: 10.1016/j.vaccine.2022.03.015 |
| Human TLR4 Reporter HEK293 Cells (NF-κB) | Modulation of outer membrane vesicle-based immune responses by cathelicidins. | 2022 | Vaccine | Balhuizen M.D. et al. | DOI: 10.1016/j.vaccine.2022.03.015 |
| Human TLR3 Reporter HEK293 Cells (NF-κB) | Modulation of outer membrane vesicle-based immune responses by cathelicidins. | 2022 | Vaccine | Balhuizen M.D. et al. | DOI: 10.1016/j.vaccine.2022.03.015 |
| Human TLR5 Reporter HEK293 Cells (NF-κB) | Modulation of outer membrane vesicle-based immune responses by cathelicidins. | 2022 | Vaccine | Balhuizen M.D. et al. | DOI: 10.1016/j.vaccine.2022.03.015 |
| QUANTI-Blue™ | Modulation of outer membrane vesicle-based immune responses by cathelicidins. | 2022 | Vaccine | Balhuizen M.D. et al. | DOI: 10.1016/j.vaccine.2022.03.015 |
| HEK-Blue™ Null1 Cells | Modulation of outer membrane vesicle-based immune responses by cathelicidins. | 2022 | Vaccine | Balhuizen M.D. et al. | DOI: 10.1016/j.vaccine.2022.03.015 |
| Human TLR9 Reporter HEK293 Cells (NF-κB) | Modulation of outer membrane vesicle-based immune responses by cathelicidins. | 2022 | Vaccine | Balhuizen M.D. et al. | DOI: 10.1016/j.vaccine.2022.03.015 |
| Normocin® - Antimicrobial Reagent | Modulation of outer membrane vesicle-based immune responses by cathelicidins. | 2022 | Vaccine | Balhuizen M.D. et al. | DOI: 10.1016/j.vaccine.2022.03.015 |
| Human TLR2 Reporter HEK293 Cells (NF-κB) | Modulation of outer membrane vesicle-based immune responses by cathelicidins. | 2022 | Vaccine | Balhuizen M.D. et al. | DOI: 10.1016/j.vaccine.2022.03.015 |
| Zeocin® | Modulation of outer membrane vesicle-based immune responses by cathelicidins. | 2022 | Vaccine | Balhuizen M.D. et al. | DOI: 10.1016/j.vaccine.2022.03.015 |
| QUANTI-Luc™: Luciferase Detection Reagent | A nanovaccine for enhancing cellular immunity via cytosolic Co-delivery of an... | 2022 | J Control Release | Carson C.S. et al. | DOI: 10.1016/j.jconrel.2022.03.020 |
| QUANTI-Blue™ | A nanovaccine for enhancing cellular immunity via cytosolic Co-delivery of an... | 2022 | J Control Release | Carson C.S. et al. | DOI: 10.1016/j.jconrel.2022.03.020 |
| THP1-Dual™ Cells | A nanovaccine for enhancing cellular immunity via cytosolic Co-delivery of an... | 2022 | J Control Release | Carson C.S. et al. | DOI: 10.1016/j.jconrel.2022.03.020 |
| CD40L Reporter HEK 293 Cells | The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual m... | 2022 | J Immunother Cancer | Sum E. et al. | DOI: 10.1136/jitc-2021-003264 |
| Poly(I:C) (HMW) VacciGrade™ | The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual m... | 2022 | J Immunother Cancer | Sum E. et al. | DOI: 10.1136/jitc-2021-003264 |
| FLA-ST (Standard or Ultrapure) | L-plastin enhances NLRP3 inflammasome assembly and bleomycin-induced lung fib... | 2022 | Cell Rep. | Joshi H. et al. | DOI: 10.1016/j.celrep.2022.110507 |
| LPS-EB (LPS from E. coli O111:B4) | L-plastin enhances NLRP3 inflammasome assembly and bleomycin-induced lung fib... | 2022 | Cell Rep. | Joshi H. et al. | DOI: 10.1016/j.celrep.2022.110507 |
| NLRP3 inflammasome inhibitor - MCC950 | Targeting NLRP3 inflammasome modulates gut microbiota, attenuates corticospin... | 2022 | Biomed Pharmacother. | Xiao L. et al. | DOI: 10.1016/j.biopha.2022.112797 |
| ODN 2006 (ODN 7909) | An optimized measles virus glycoprotein-pseudotyped lentiviral vector product... | 2022 | STAR Protoc. | Vamva E. et al. | DOI: 10.1016/j.xpro.2022.101228 |